Philippe L. Bédard

22.9k total citations · 5 hit papers
347 papers, 9.7k citations indexed

About

Philippe L. Bédard is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Philippe L. Bédard has authored 347 papers receiving a total of 9.7k indexed citations (citations by other indexed papers that have themselves been cited), including 191 papers in Oncology, 127 papers in Cancer Research and 115 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Philippe L. Bédard's work include Cancer Genomics and Diagnostics (96 papers), Testicular diseases and treatments (55 papers) and Cancer Immunotherapy and Biomarkers (55 papers). Philippe L. Bédard is often cited by papers focused on Cancer Genomics and Diagnostics (96 papers), Testicular diseases and treatments (55 papers) and Cancer Immunotherapy and Biomarkers (55 papers). Philippe L. Bédard collaborates with scholars based in Canada, United States and Spain. Philippe L. Bédard's co-authors include Lillian L. Siu, Aaron R. Hansen, Mark J. Ratain, Martine Piccart, David M. Hyman, Matthew S. Davids, Ben Tran, Janet Dancey, Eitan Amir and Nicole Onetto and has published in prestigious journals such as Nature, Cell and The Lancet.

In The Last Decade

Philippe L. Bédard

329 papers receiving 9.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour heterogeneity in the clinic

2013 897 citations Philippe L. Bédard, Aaron R. Hansen et al. profile →
Small molecules, big impact: 20 years of targeted therapy in oncology

2020 416 citations Philippe L. Bédard, Lillian L. Siu et al. profile →
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

2018 391 citations Philippe L. Bédard, Lajos Pusztai et al. Annals of Oncology profile →
Novel patterns of response under immunotherapy

2019 354 citations Philippe L. Bédard et al. Annals of Oncology profile →
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

2021 257 citations Giuseppe Curigliano, Hans Gelderblom et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Philippe L. Bédard

Since Specialization

Citations

This map shows the geographic impact of Philippe L. Bédard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe L. Bédard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe L. Bédard more than expected).

Fields of papers citing papers by Philippe L. Bédard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe L. Bédard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe L. Bédard. The network helps show where Philippe L. Bédard may publish in the future.

Co-authorship network of co-authors of Philippe L. Bédard

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe L. Bédard. A scholar is included among the top collaborators of Philippe L. Bédard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe L. Bédard. Philippe L. Bédard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Final results of the investigator-initiated phase II BEAVER trial.	Journal of Clinical Oncology	April A. N. Rose, Ian King et al.	2
2	Clinical Utility of Tumor Next-Generation Sequencing Panel Testing to Inform Treatment Decisions for Patients With Advanced Solid Tumors in a Tertiary Care Center	JCO Precision Oncology	Ramy Saleh, Lisa Avery et al.	2
3	Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set	JCO Precision Oncology	Kenneth L. Kehl, Jessica A. Lavery et al.	1
4	375TiP A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors	Annals of Oncology	Ludimila Cavalcante, Lillian L. Siu et al.	1
5	Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103)	The Journal of Clinical Pharmacology	Elena Garralda, Do Youn Oh et al.	9
6	Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens	Cancer Research Communications	Josep Tabernero, Philippe L. Bédard et al.	9
7	Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study	Journal of Clinical Oncology	Michael J. Raphael, Sumit Gupta et al.	20
8	Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors breakdown →	Clinical Cancer Research	Giuseppe Curigliano, Hans Gelderblom et al.	257
9	Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study	npj Breast Cancer	Mitchell J. Elliott, Marguerite Ennis et al.	9
10	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer	Current Oncology	Domen Ribnikar, Igor Stukalin et al.	9
11	Characterization and outcomes of patients enrolled to multiple phase I cancer trials	Cancer Chemotherapy and Pharmacology	Lina Chen, Lisa Wang et al.	1
12	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer	Clinical Cancer Research	Maura N. Dickler, Cristina Saura et al.	57
13	Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients	Clinical Cancer Research	Britt I. Drögemöller, Beth Brooks et al.	28
14	Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours	British Journal of Urology	Jeremy Lewin, Laleh Soltan Ghoraie et al.	8
15	A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma	European Urology Focus	Ricardo Leão, Madhur Nayan et al.	22
16	A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors	Clinical Cancer Research	Kyriakos P. Papadopoulos, Robin Kate Kelley et al.	59
17	Promising SINEs for Embargoing Nuclear–Cytoplasmic Export as an Anticancer Strategy	Cancer Discovery	David S.P. Tan, Philippe L. Bédard et al.	75
18	A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors	Clinical Cancer Research	Philippe L. Bédard, Josep Tabernero et al.	257
19	Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?	Cancer Research	Christos Hatzis, Philippe L. Bédard et al.	67
20	Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling	Clinical Cancer Research	Hatem A. Azim, Stefan Michiels et al.	278

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact